Vaxart (merged with Aviragen Therapeutics)'s Series B - III Round

Vaxart (merged with Aviragen Therapeutics) raised a round of funding on June 29, 2012.

Vaxart has developed a vaccine delivery system that greatly enhances the adaptive immune response to orally delivered antigens. The vaccine system provides a key stimulatory signal (double-stranded RN…

Articles about Vaxart (merged with Aviragen Therapeutics)'s Series B - III Round: